European and Developing Countries Clinical Trials Partnership

rdf:langString European and Developing Countries Clinical Trials Partnership

rdf:langString InternetArchiveBot

rdf:langString November 2022

rdf:langString yes

rdf:langString The European and Developing Countries Clinical Trials Partnership (EDCTP) is a partnership between the European Union (EU), Norway, Switzerland and developing countries and other donors, as well as the pharmaceutical industry, to enable clinical trials and the development of new medicines and vaccines against HIV/AIDS, tuberculosis, and malaria.[2] The need for global action against these diseases in order to promote poverty reduction has been recognised by the United Nations, the G8, and the African Union, and the program envisioned the provision of €600 million for the period 2003–2007 in order to translate medical research results into clinical applications relevant to the needs of developing countries. The European Council adopted the Programme for Action: Accelerated action on HIV/AIDS, malaria and tuberculosis in the context of poverty reduction (COM (2001)96, [3]) on 15 May 2001, following its launch by the European Commission. The Commission proposal was adopted on 16 June 2003 by the Council and the European Parliament.[4] The Programme was to be based on three central pillars: "the impact of existing interventions, the affordability of key pharmaceuticals and trade, and the research and development of specific global public goods."[5] These aims relate specifically with the EU stance on access to essential medicines. [6]